The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

A nationwide policy shift implemented in 2018 was designed to, among other things, improve the waiting list mortality rate. One unintended consequence, however, is that patients are now more likely to experience a stroke after receiving a new heart.

Bioresorbable stents are back in the spotlight thanks to some significant progress from multiple medtech companies. Eric Secemsky, MD, discussed some of the biggest breakthroughs in this space at CRT 2025.

One product is being pulled from the market, and the other is receiving updated instructions for use.

Researchers developed several new AI models that could guide the management of patients with non-valvular atrial fibrillation. There is still some work to do in terms of accuracy, but they already appear to outperform the traditional risk scores being used today.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH.